Infections in patients with acute luekemia treated with different regimens
https://doi.org/10.21294/1814-4861-2025-24-2-108-116
Abstract
Patients with acute leukemia are characterized by a high risk of infectious complications due to severe neutropenia, which occurs in most cases of modern treatment regimens. Despite the improvement in cytotoxic and concomitant treatment, infectious remain the main cause of induction mortality. Aim of the study: to analyze the frequency and structure of infectious complications in patients with acute leukemia, who received different chemotherapy regimens. Material and Methods. The retrospective analysis included 40 patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). 30 patients with AML underwent 97 chemotherapy courses which included 7 + 3 program (n=53), low-intensity protocols: azacytidine in combination with venetoclax (n=26), Aza-Ida-Ara-C (n=13), low doses of cytarabine (n=3) and high-dose anti-relapse chemotherapy programs (n=2). 10 patients with ALL received 43 chemotherapy courses: ALL-2009 program (n=41), anti-relapse protocols (n=2). The frequency and duration of myelotoxic agranulocytosis, episodes of infections and the variety of microorganisms in different loci were analyzed. Statistical analysis was performed using the Statteсh v. 4.1.2 program. Results. The median duration of myelotoxic agranulocytosis was significantly higher in patients with AML, treated with 7 + 3 protocol, especially during courses of induction of remission. The most common infectious complications were pneumonia, sepsis, febrile neutropenia, and mucositis. Necrotic enteropathy and stomatitis were significantly more common for AML patients compared to ALL patients (22.7 and 7.0 %, (p=0.025); 18.6 and 2.3 %, (p=0.01), respectively). The most common etiologic factors of infections in patients with acute leukemia were gram-negative microorganisms from Enterobacteriaceae family (40.57 %) and non-fermenting bacteria (15.66 %). The detection rate of metallo-beta-lactamase-producing enterobacteria was 12.45 %. The first-line antibacterial therapy (third-generation cephalosporins with beta-lactamase inhibitor) was effective in 21.62 %, and the secondline therapy effectiveness did not exceed 8.2 %. The choice of third and subsequent line antibiotics in most cases was made taking into account the results of microbiological tests, which increased its effectiveness to 41.54 %. The greatest effectiveness was demonstrated by a combination of two carbapenems (17.07 %), and cefoperazone/sulbactam or carbapenem + co-trimoxazole (19.51 %). Conclusion. Thus, patients with acute leukemia have a high prevalence of carbapenem-resistant gram-negative infections.
About the Authors
T. N. AleksandrovaRussian Federation
Tuiara N. Aleksandrova, MD, PhD, Hematologist, Hematology Department; Associate Professor, Department of Hospital Therapy, Professional Diseases and Clinical Pharmacology, Institute of Medicine
Researcher ID (WOS): R-1072-2018
4 km Sergelyakhskoye shosse, Yakutsk, 677000
58, Belinsky St., Yakutsk, 677000
V. N. Yadrikhinskaya
Russian Federation
Vera N. Yadrikhinskaya, MD, PhD, Associate Professor, Department of Hospital Therapy, Professional Diseases and Clinical Pharmacology, Institute of Medicine
58, Belinsky St., Yakutsk, 677000
I. I. Mulina
Russian Federation
Inna I. Mulina, Chief Hematologist of the Ministry of Health of the Republic of Sakha (Yakutia), Head of Hematology Department of the Clinical Center
4 km Sergelyakhskoye shosse, Yakutsk, 677000
References
1. Cordonnier C., Ljungman P., Cesaro S., Hirsch H.H., Maschmeyer G., von Lilienfeld-Toal M., Vehreschild M., Mikulska M., Emonts M., Gennery A.R., Neofytos D., Bochud P.Y., Einsele H., Maertens J. The EHA Research Roadmap: Infections in Hematology. Hemasphere. 2021; 5(12). doi: 10.1097/HS9.0000000000000662.
2. Torres-Flores J., Espinoza-Zamora R., Garcia-Mendez J., CerveraCeballos E., Sosa-Espinoza A., Zapata-Canto N. Treatment-Related Mortality From Infectious Complications in an Acute Leukemia Clinic. J Hematol. 2020; 9(4): 123–31. doi: 10.14740/jh751.
3. Righi E., Peri A.M., Harris P.N., Wailan A.M., Liborio M., Lane S.W., Paterson D.L. Global prevalence of carbapenem resistance in neutropenic patients and association with mortality and carbapenem use: systematic review and meta-analysis. J Antimicrob Chemother. 2017; 72(3): 668–77. doi: 10.1093/jac/dkw459.
4. De Angelis G., Fiori B., Menchinelli G., D’Inzeo T., Liotti F.M., Morandotti G.A., Sanguinetti M., Posteraro B., Spanu T. Incidence and antimicrobial resistance trends in bloodstream infections caused by ESKAPE and Escherichia coli at a large teaching hospital in Rome, a 9-year analysis (2007–2015). Eur J Clin Microbiol Infect Dis. 2018; 37(9): 1627–36. doi: 10.1007/s10096-018-3292-9.
5. Pouch S.M., Satlin M.J. Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies. Virulence. 2017; 8(4): 391–402. doi: 10.1080/21505594.2016.1213472.
6. Abramova A.V., Abdullaev A.O., Azimova M.Kh., et al.; edited by prof. V.G. Savchenko. Diagnostic algorithms and treatment protocols for blood system diseases (Klyasova G. A. Antimicrobial therapy; Vol. 2. Moscow, 2018. P. 1067–113. (in Russian). ISBN: 978-5-89816-166-8. EDN: YXMBHJ.
7. Acute myeloid leukemia: clinical guidelines of the Ministry of Health of the Russian Federation. 2024. (in Russian). [Internet]. [cited 14.04.2025]. URL: https://cr.minzdrav.gov.ru/preview-cr/131_2.
8. Parovichnikova E.N., Garmaeva T.T., Lazareva O., Lukina K., Chabaeva Yu, Kulikov S., Troitskaya V., Gaponova T.V., Menshikova L.I., Savchenko V.G. A Rationale for a New Operational Integrated Quality and Efficiency Index f or Assessing the Performance of Hematological Services in Constituent Entities of the Russian Federation. Clinical Oncohematology. 2022; 15(1): 1–15. (in Russian). doi: 10.21320/2500-2139-2022-15-1-1-15. EDN: WHISRL.
9. McMahon S., Sahasrabhojane P., Kim J., Franklin S., Chang C.C., Jenq R.R., Hillhouse A.E., Shelburne S.A., Galloway-Peña J. Contribution of the Oral and Gastrointestinal Microbiomes to Bloodstream Infections in Leukemia Patients. Microbiol Spectr. 2023; 11(3). doi: 10.1128/spectrum.00415-23.
10. DiNardo C.D., Jonas B.A., Pullarkat V., Thirman M.J., Garcia J.S., Wei A.H., Konopleva M., Döhner H., Letai A., Fenaux P., Koller E., Havelange V., Leber B., Esteve J., Wang J., Pejsa V., Hájek R., Porkka K,. Illés Á., Lavie D., Lemoli R.M., Yamamoto K., Yoon S.S., Jang J.H., Yeh S.P., Turgut M., Hong W.J., Zhou Y., Potluri J., Pratz K.W. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020; 383(7): 617–29. doi: 10.1056/NEJMoa2012971.
11. Othman T.A., Tenold M.E., Moskoff B.N., Azenkot T., Jonas B.A. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia. Expert Rev Hematol. 2021; 14(5): 407–17. doi: 10.1080/17474086.2021.1938533.
12. Matthews A. H., Perl A. E., Luger S. M., Gill S. I., Lai C., Porter D.L., Skuli S., Bruno X. J., Carroll M. P, Freyer C. W., Carulli A., Babushok D. V., Frey N. V., Hexner E. O., Martin M. E., McCurdy S. R., Stadtmauer E. A., Loren A. W., Paralkar V. R., Maillard I. P., Pratz K.W. Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol. 2023; 98(8): 1254–64. doi: 10.1002/ajh.26991.
13. Poddubnaja I.V. Vedenie pacientov onkogematologicheskogo profilja v period pandemii COVID-19. Moscow, 2022. 140 p. (in Russian). ISBN: 978-5-907427-70-9. EDN: LASYOE.
14. Akhmedov M.I., Klyasova G.A., Parovichnikova E.N. Infectious complications and their contributing risk factors after allogeneic hematopoietic stem cell transplantation. Russian Journal of Hematology and Transfusiology. 2022; 67(1): 90–107. (in Russian). doi: 10.35754/0234-5730-2022-67-1-90-107. EDN: IEGBWC.
15. Suhorukova M.V., Jejdel’shtejn M.V., Ivanchik N.V. et.al. Antimicrobial resistance of nosocomial Enterobacterales isolates in Russia: results of multicenter epidemiological study “MARATHON 2015–2016”. Clinical Microbiology and Antimicrobial Chemotherapy. 2019; 21(2): 147–59. (in Russian). doi: 10.36488/cmac.2019.2.147-159. EDN: QDARVM.
16. Scheich S., Weber S., Reinheimer C., Wichelhaus T.A., Hogardt M., Kempf VAJ., Kessel J., Serve H., Steffen B. Bloodstream infections with gram-negative organisms and the impact of multidrug resistance in patients with hematological malignancies. Ann Hematol. 2018; 97(11): 2225–34. doi: 10.1007/s00277-018-3423-5.
17. Klyasova G.A. Current treatment options for infections caused by carbapenem-resistant Enterobacteriaceae in patients with hematological malignancies. Oncohematology. 2020; 15(2): 92–107. (in Russian). doi: 10.17650/1818-8346-2020-15-2-92-107. EDN: OHTLXW.
18. Klyasova G.А., Malchikova A.O., Tandilova K.S., Blokhina E.V., Parovichikova E.N., Kravchenko S.K., Savchenko V.G. Treatment of candidemia caused by Candida albicans and Candida nonalbicans in patients with hematological malignancies. Therapeutic Archive. 2019; 91(8): 84–92. (in Russian). doi: 10.26442/00403660.2019.08.000385. EDN: HAXAUX.
19. Azoulay E., editors. Pulmonary Involvement in Patients with Hematological Malignancies. (Soubani A.O. Respiratory Infections in Patients with Hematological Malignancies. Berlin Heidelberg: Springer-Verlag; 2011. P. 9–38. ISBN-10: 3642157416. ISBN-13: 978-3642157417).
20. Nucci M., Spector N., Bueno A.P., Solza C., Perecmanis T., Bacha P.C., Pulcheri W. Risk factors and attributable mortality associated with superinfections in neutropenic patients with cancer. Clin Infect Dis. 1997; 24(4): 575–79. doi: 10.1093/clind/24.4.575.
21. De Neve N.Y., Benoit D.D., Depuydt P.O., Offner F.C., Nollet J., Noens L.A., Decruyenaere J.M. Aspiration pneumonia: an underestimated cause of severe respiratory failure in patients with haematological malignancies and severe oral mucositis? Acta Clin Belg. 2010; 65(6): 416–19. doi: 10.1179/acb.2010.65.6.008.
Review
For citations:
Aleksandrova T.N., Yadrikhinskaya V.N., Mulina I.I. Infections in patients with acute luekemia treated with different regimens. Siberian journal of oncology. 2025;24(2):108-116. (In Russ.) https://doi.org/10.21294/1814-4861-2025-24-2-108-116